GBI: Breast cancer drug pipeline booming
LONDON — GBI Research’s latest report is highlighting the big potential breast cancer drugs have to impact the market in the next 10 years. The report, “Frontier Pharma: Breast Cancer” found that there are currently 1,050 drugs in active development to treat breast cancer. Among them are 289 first-in-class drugs that haven’t yet been involved in a licensing of co-development deal.
“Breast cancer has the largest product pipeline in the pharmaceutical industry, and its significant patient population and successful commercialization of drugs such as Herceptin have attracted a great deal of R&D investment,” managing analyst Dominic Trewartha said.
Trewartha added that the number of treatments being developed points to a better understanding of some molecules that research suggests play a role in the disease’s initiation and progression.
“Although the development of products for novel molecular targets is risky, as their role in disease pathophysiology is often poorly characterized, the breast cancer pipeline also has the potential to yield therapies that outperform existing products and mechanisms of action,’ he said.
Pharmacy Quality Alliance adds 3 new board members
SPRINGFIELD, Va. — The Pharmacy Quality Alliance announced Tuesday that it has added three members to its board. The new additions are Jason Ausili, director of pharmacy affairs for the National Association of Chain Drug Stores (NACDS); American Medical Group Association (AMGA) chief medical and quality officer Dr. Jerry Penso; and Pharmaceutical Research and Manufacturers of America (PhRMA) EVP policy & research and membership Lori Reilly.
Ausili is responsible for leading NACDS’ pharmacy quality efforts and representing chain community pharmacy representing chain community pharmacy member on the advancement of value and team-based care models. Penso, who is also president of AMGA’s foundation, leads learning collaboratives for best practices and the organization’s national hypertension campaign. At PhRMA, Reilly oversees its development of policy and legislative analysis, as well as research studies about health care issues that affect biopharmaceutical companies.
“I am pleased to have the opportunity work with these individuals who have a demonstrated commitment to PQA's mission of developing meaningful measures of appropriate medication use and patient safety that can drive overall patient outcomes, and enhance the patient experience,” PQA executive director Laura Cranston said. “Their combined expertise and unique backgrounds will provide the leadership and engagement necessary to continue to advance the appropriate uptake and implementation of performance measures in new and evolving models of care.”
Benzer Pharmacy opens fourth new store in 2016
PINELLAS PARK, Fla. — Benzer Pharmacy opened a new store here Tuesday, the chain’s fourth new store since the year began. The new location will offer specialty medications for such complex chronic conditions as HIV and rheumatoid arthritis.
“We are one of the fastest growing private companies in America,” Benzer pharmacist Kevin Shukla said at the new location. “Following this rapid growth, the pharmacy is ensuring that we reach more customers and guarantee that their experiences match their expectations.”
Shukla also touted the role medication synchronization, which Benzer says has gained traction in the community, can play in adherence.
“Medication synchronization also known as med sync, allows patients to pick up all their ongoing prescription refills at the pharmacy on a single, convenient day each month and work closely with the pharmacist on sticking to their medication regime,” he said. “In addition, the once a month appointment day facilitates increased pharmacist-patient dialogue and allows time for additional patient care services.”
Loading Post Please Wait...